A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors ; volume:31 ; number:2 ; day:15 ; month:12 ; year:2012 ; pages:409-416 ; date:4.2013
Investigational new drugs ; 31, Heft 2 (15.12.2012), 409-416, 4.2013
- Classification
-
Medizin, Gesundheit
- Creator
-
Gordon, Michael S.
Mendelson, David S.
Gross, Mitchell
Uttenreuther-Fischer, Martina
Ould-Kaci, Mahmoud
Zhao, Yihua
Stopfer, Peter
Agus, David B.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-012-9904-9
- URN
-
urn:nbn:de:101:1-2019060823320825478397
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gordon, Michael S.
- Mendelson, David S.
- Gross, Mitchell
- Uttenreuther-Fischer, Martina
- Ould-Kaci, Mahmoud
- Zhao, Yihua
- Stopfer, Peter
- Agus, David B.
- SpringerLink (Online service)
Other Objects (12)
Phase I dose-escalation oncology trials with sequential multiple schedules
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
PK/PD modeling supports the dose-escalation decision in VIKING
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
Phase I dose-escalation oncology trials with sequential multiple schedules
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
PK/PD modeling supports the dose-escalation decision in VIKING
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study
Phase I dose-escalation oncology trials with sequential multiple schedules
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
PK/PD modeling supports the dose-escalation decision in VIKING
Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study